1 **Epidemiology of *Burkholderia pseudomallei, Streptococcus suis, Salmonella***

2 ***spp., Shigella* spp. and *Vibrio* spp. infections in 111 hospitals in Thailand, 2022**

3

4 Charuttaporn Jitpeera[a], Somkid Kripattanapong[a], Preeyarach Klaytong[b], Chalida

5 Rangsiwutisak[b], Prapass Wannapinij[b], Pawinee Doungngern[a], Papassorn

6 Pinyopornpanish[c], Panida Chamawan[d], Voranadda Srisuphan[d], Krittiya

7 Tuamsuwan[d], Phairam Boonyarit[d], Orapan Sripichai[e], Soawapak Hinjoy[f], John

8 Stelling[g], Paul Turner[b,h,i], Wichan Bhunyakitikorn[a], Sopon Iamsirithaworn[j], Direk

9 Limmathurotsakul[b,i,k]∗

10

11 **Affiliation:**

12 *[a] Division of Epidemiology, Department of Disease Control, Ministry of Public Health,*

13 *Nonthaburi 11000, Thailand*

14 *[b] Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol*

15 *University, Bangkok, 10400, Thailand*

16 *[c] Division of Communicable Diseases, Department of Disease Control, Ministry of Public Health,*

17 *Nonthaburi, 11000, Thailand*

18 *[d] Health Administration Division, The Office of Permanent Secretary, Ministry of Public Health,*

19 *Nonthaburi, 11000, Thailand*

20 *[e] Department of Medical Science, Ministry of Public Health, Nonthaburi, 11000, Thailand (OS)*

21 *[f] Office of International Cooperation, Department of Disease Control, Ministry of Public Health,*

22 *Nonthaburi 11000, Thailand (SH)*

^g Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States (JS)

^h Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap,

Cambodia

ⁱ Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United

Kingdom

^j Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand (SI)

^k Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok,

10400, Thailand

ORCID

Charuttaporn Jitpeera 0009-0007-9298-5853

Preeyarach Klaytong 0000-0002-9906-5159

Chalida Rangsiwutisak 0009-0007-9380-9085

Paul Turner 0000-0002-1013-7815

Direk Limmathurotsakul 0000-0001-7240-5320

* **Corresponding author**: Prof. Direk Limmathurotsakul, Mahidol-Oxford Tropical Medicine

Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok,

10400, Thailand. Tel: +66 2 203 6333, Fax: +66 2 354 9169, e-mail: direk@tropmedres.ac

Abstract

The information on notifiable diseases in low- and middle-income countries is often incomplete, limiting our understanding of their epidemiology. Our study addresses this knowledge gap by analyzing microbiology laboratory and hospital admission data from 111 of 127 public referral hospitals in Thailand, excluding Bangkok, from January to December 2022. We evaluated factors associated with the incidence of notifiable bacterial diseases (NBDs) caused by 11 pathogens; including *Brucella* spp., *Burkholderia pseudomallei*, *Corynebacterium diphtheriae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, non-typhoidal *Salmonella* spp. (NTS), *Salmonella enterica* serovar Paratyphi, *Salmonella enterica* serovar Typhi, *Shigella* spp., *Streptococcus suis*, and *Vibrio* spp.. We used multivariable Poisson random-effects regression models. Additionally, we compared their yearly incidence rates in 2022 with those from 2012-2015 in hospitals where paired data were available. In 2022, the NBD associated with the highest total number of deaths was *B. pseudomallei* (4,407 patients; 1,219 deaths) infection, followed by NTS (4,501 patients; 461 deaths) and *S. suis* (867 patients, 134 deaths) infection. The incidence rate of *B. pseudomallei* and *S. suis* infection was highest in the northeast and upper central, respectively. The incidence rate of NTS infection was not associated with geographical region. The yearly incidence rate of *B. pseudomallei* and *S. suis* infection in 2022 were higher than those between 2012-2015, while those of fecal-oral transmitted NBDs including NTS infection, typhoid, shigellosis and vibriosis were lower. Overall, *B. pseudomallei* and *S. suis* infection are emerging and associated with a high number of deaths in Thailand. Specific public health interventions are warranted.

Keywords: melioidosis; salmonella; shigella; *Streptococcus suis*; vibrio; incidence; mortality

Introduction

Timely, reliable and complete information regarding notifiable diseases is essential for disease control and prevention, and enhancing our understanding of their epidemiology [1-3]. To achieve timeliness and completeness in data reporting, many high-income and upper-middle-income countries have strengthened their national surveillance systems by modernizing tools, technology and strategies [4-6]. These include automatic electronic laboratory-based reporting of notifiable diseases [5-7]. However, most low and middle-income countries (LMICs) have a shortage of resources, still use conventional or semi-automated data reporting systems, and do not automatically integrate laboratory data into their surveillance systems [4,8]. Therefore, the information available in the national surveillance systems of LMICs are still largely incomplete [9-11] and our understanding of their epidemiology remains limited.

In Thailand, the national surveillance systems monitors 13 dangerous communicable diseases and 57 notifiable diseases, overseen by the Department of Disease Control (DDC), Ministry of Public Health (MoPH) [12]. For the 13 dangerous communicable disease (e.g. Ebola and smallpox), immediate reporting of any suspected cases is required. For the 57 notifiable diseases, the reporting systems can be semi-automatic, utilizing the electronic data of final diagnosis based on the International Classification of Diseases, 10th revision (ICD-10) recorded in the hospital information systems (HIS). However, the ICD-10 is reliable only in few conditions [13,14] and the surveillance systems do not utilize microbiology laboratory data. Recent studies showed that many public hospitals, which have microbiology laboratories, do not report most cases and deaths following culture-confirmed notifiable bacterial diseases (NBDs) to the national

surveillance systems [11,15]. The incomplete data hinders efforts to improve awareness, control,

prevention, and our understanding of NBDs in the country [16].

To overcome limitations in LMICs, we developed the AMASS (AutoMated tool for

Antimicrobial resistance Surveillance System), an offline application that enables hospitals to

automatically analyse and generate standardized antimicrobial resistance (AMR) surveillance

reports from routine microbiology and hospital data [17]. The AMASS version 1.0 was released

on 1st February 2019 and tested in seven hospitals in seven countries [17]. We conceptualized

that the AMASS could additionally analyse and generate summary reports for multiple NBDs

[18]. The AMASS version 2.0 (AMASSv2.0) was released on 16th May 2022 and tested using

data of 49 public hospitals in Thailand from 2012 to 2015 [15]. We demonstrate that national

statistics on NBDs in LMICs could be improved by integrating information from readily

available databases [15]. In 2023, collaborating with Health Administration Division, MoPH

Thailand, we implemented AMASSv2.0 in 127 public hospitals in Thailand using the data from

2022 [19]. We recently reported the epidemiology of AMR bloodstream infections in 111

hospitals [20].

Here we aimed to evaluate the epidemiology of multiple NBDs in 111 hospitals in Thailand

using the data from 2022. We also examined the trends of each NBD by comparing the data from

2022 with the data from 2012 to 2015.

Methods

Study setting

In 2022, Thailand had a population of 66.1 million, consisted of 77 provinces, and covered

513,120 km^2. The health systems in each province were integrated into 12 groups of provinces,

known as health regions, plus the capital Bangkok as health region 13 (Figure 1), using the

concept of decentralization [21]. The Health Administration Division, Ministry of Public Health

(MoPH) Thailand, supervised 127 public referral hospitals in health regions 1 to 12. These

included 35 advanced-level referral hospital (i.e. level A, with a bed size of about 500-1,200

beds), 55 standard-level referral hospital (i.e. level S, with a bed size of about 300 to 500) and 37

mid-level referral hospital (i.e. level M1, with a bed size of about 180-300) [22]. All level A and

S hospitals, and most of level M1 hospitals were equipped with a microbiology laboratory

capable of performing bacterial culture using standard methodologies for bacterial identification

and susceptibility testing provided by the Department of Medical Sciences, MoPH, Thailand [23].

From 16 December 2022 to 30 June 2023, on behalf of the Health Administration Division,

MoPH, we invited and trained 127 public referral hospitals in health regions 1 to 12 to utilize the

AMASS with their own microbiology and hospital admission data files via four online meetings,

five face-to-face meetings and on-line support [20]. Subsequently, the hospitals that completed

utilization of the AMASS submitted summary data generated by the tool to the MoPH [20].

Study design

We conducted a retrospective study evaluating epidemiology of selected NBDs diagnosed by

culture using microbiology laboratory and hospital admission data from 2022. We also compared

the yearly incidence rates of each NBD in 2022 with those from 2012-2015, using paired data

from 49 public referral hospitals that were previously published [15].

The NBDs under evaluation included infections caused by 12 pathogens; *Brucella* spp.,

Burkholderia pseudomallei, *Corynebacterium diphtheriae*, *Neisseria gonorrhoeae, Neisseria*

meningitidis, Non-typhoidal *Salmonella* spp., *Salmonella enterica* serovar Paratyphi, *Salmonella*

enterica serovar Typhi, *Shigella* spp., *Streptococcus suis*, and *Vibrio* spp. infections. NBD cases

were defined as having any clinical specimen (including blood, respiratory tract specimens, urine,

stool, cerebrospinal fluid, genital swabs and other specimens) culture positive for a pathogen.

The AMASS merged microbiology laboratory and hospital admission data using the hospital

number (i.e. the patient identifier) present in both data files. Then, the AMASS deduplicated the

data reporting total number of inpatients with a clinical specimen culture positive for a pathogen

during the evaluation period.[11] Mortality was defined using the discharge summary (in the

hospital admission data) which was routinely completed by the attending physician and reported

to the MoPH. For each NBD, in case that a patient was admitted with that NBD more than once

during the evaluation period, the mortality outcome of the first admission was presented.

Statistical Analysis

Data were summarized with medians and interquartile ranges (IQR) for continuous measures,

and proportions for discrete measures. IQRs are presented in terms of 25th and 75th percentiles.

Continuous variables and proportions were compared between groups using Kruskal Wallis tests

and Chi-square tests, respectively.

For NBDs with more than 100 cases in the year 2022, we evaluated factors associated with the

incidence rate of NBDs per 100,000 population using multivariable Poisson random-effects

regression models [24]. The total number of NBD cases in each province was calculated by

summing the number of NBD cases from all hospitals located in the same province. We assumed

that the distribution of province-specific random effects was normal. Factors evaluated included

health region, Gross Provincial Product (GPP), pig density and poultry density. Data of GPP in

2021 [25] were used as a proxy for the size of the economy in each province. Pig density and

poultry density (per square meters) were estimated by using the total number of pigs and poultry

in each province in Thailand in 2022, divided by the total area of each province [26].

Additionally, we compared the yearly incidence rates of each NBD in 2022 with the those

between 2012-2015 in hospitals where paired data were available. Multivariable Poisson

random-effects regression models were used to evaluate the change of incidence rate per 100,000

population between the time periods. We also compared the total number of cases and deaths of

each NBD diagnosed by culture in 2022 in our study with those of relevant notifiable diseases

reported to the NNDSS of Thailand [27]. We used STATA (version 14.2; College Station,

Texas) for all analyses (Appendix A).

Data availability

The hospital-level summary data used for the study are open-access and available at

https://figshare.com/s/79f2b4b9422263b9048b.

Ethics

Ethical permission for this study was obtained from the Institute for the Committee of the

Faculty of Tropical Medicine, Mahidol University (TMEC 23-085). Individual patient consent

was not sought as this was a retrospective study, and the Ethical and Scientific Review

Committees approved the process.

Results

Baseline characteristics

Of 127 public referral hospitals, 116 (91%) used the AMASS to analyze their microbiology and

hospital admission data files, and submitted the summary AMR and NBD data from 2022 to the

MoPH. Four hospitals had incomplete microbiology data, and one hospital had incomplete

hospital admission data. These hospitals were removed from the analysis. Therefore, a total of

111 hospitals were included in the final analysis.

Of all public referral hospitals in Thailand, 100% of Level A hospitals (35/35), 89% of Level S

hospitals (49/55) and 73% of Level M1 hospitals (27/37) were included in this study. Data were

available from 74 of 77 provinces (96%) in Thailand, all provinces except Mae Hong Son,

Nakorn Nayok and Bangkok.

A total of 46 hospitals in 42 provinces had paired data from 2022 and 2012-2015.

Brucella **spp.**

In 2022, there were 11 cases with culture-confirmed *Brucella* spp. infection (Figure 2A) and 1 of

them died (in-hospital mortality 9%). Among provinces where paired data were available, the

incidence rate did not differ between the time periods (p=0.15).

B. pseudomallei

In 2022, there were 4,407 cases with culture-confirmed *B. pseudomallei* infection and 1,219 of them died (in-hospital mortality 27.7%). The incidence rate (Figure 2B) was highest in the northeast (health regions 7, 8, 9 and 10), followed by the upper central (health region 3), north (health region 1 and 2) east (health region 6) and south (health region 11 and 12). The incidence rate was lowest in the lower central (health region 4) and west (health region 5). In the multivariable models, health region and poultry density (adjust incidence rate ratio [aIRR] 1.31, 95%CI 1.02-1.69, p=0.04) were independently associated with the incidence of *B. pseudomallei* infection per 100,000 population (Table S1). GPP and pig density and poultry density were not independently associated with the incidence rate (both p>0.20)

Among provinces where paired data were available, the yearly incidence rate of *B. pseudomallei* infection in 2022 was higher than that between 2012-2015 by 58% (aIRR 1.58, 95%CI 1.49-1.68, p<0.001).

C. diphtheriae

In 2022, there were 10 cases with culture-confirmed *C. diphtheriae* infection (Figure 2C) and 1 of them died (in-hospital mortality 10%). Among provinces where paired data were available, the incidence rate did not differ between the time periods (p=0.29).

N. gonorrhoeae

In 2022, there were 25 cases with culture-confirmed *N. gonorrhoeae* infection (Figure 2D) and

none died. Among provinces where paired data were available, the incidence rate did not differ

between the time periods (p=0.33).

N. meningitidis

In 2022, there were 9 cases with culture-confirmed *N. meningitidis* infection (Figure 2E) and 2

died (in-hospital mortality 22%). Among provinces where paired data were available, the

incidence rate did not differ between the time periods (p=0.55).

Non-typhoidal *Salmonella* spp. (NTS)

In 2022, there were 4,501 cases with culture-confirmed NTS infection (Figure 2F) and 461 died

(in-hospital mortality 10.2%). In the multivariable models, health region, GPP, pig density and

poultry density were not associated with the incidence rate (all p>0.20, Table S2).

Among provinces where paired data were available, the yearly incidence rate of NTS cases in

2022 was lower than that between 2012-2015 by 37% (aIRR 0.63, 95%CI 0.60-0.67, p<0.001).

Salmonella enterica **serovar Paratyphi**

In 2022, there were 30 cases with culture-confirmed *Salmonella enterica* serovar Paratyphi

infection (Figure 2G) and 4 died (in-hospital mortality 13%). Among provinces where paired

data were available, the incidence rate did not differ between the time periods (p=0.39).

Salmonella enterica **serovar Typhi**

In 2022, there were 32 cases with culture-confirmed *Salmonella enterica* serovar Typhi infection

(Figure 2H) and 6 died (in-hospital mortality 19%).

Among provinces where paired data were available, the yearly incidence rate of *Salmonella*

enterica serovar Typhi infection in 2022 was lower than that between 2012-2015 by 83% (aIRR

0.17, 95%CI 0.07-0.41, p<0.001).

Shigella spp.

In 2022, there were 68 cases with culture-confirmed *Shigella* spp. infection (Figure 2I) and 4

died (in-hospital mortality 6%).

Among provinces where paired data were available, the yearly incidence rate of *Shigella* spp.

infection in 2022 was lower than that between 2012-2015 by 78% (aIRR 0.22, 95%CI 0.14-0.36,

p<0.001).

S. suis

In 2022, there were 867 cases with culture-confirmed *S. suis* infection and 134 of them died (in-

hospital mortality 15.5%). The incidence rate (Figure 2J) was highest in the upper central (health

regions 3), followed by the north (health regions 1 and 2) and northeast (health regions 7, 8, 9

and 10). The incidence rate was lowest in the south (health regions 11 and 12) and lower central

(health region 4). In the multivariable models, health region was associated with the incidence of

S. suis infection per 100,000 population (Table S3). GPP, pig density and poultry density were

not independently associated with the incidence rate.

Among provinces where paired data were available, the yearly incidence rate of *S. suis* infection

in 2022 was higher than that between 2012-2015 by 172% (aIRR 2.72, 95%CI 2.29-3.24,

p<0.001).

Vibrio **spp.**

In 2022, there were 809 cases with culture-confirmed *Vibrio* spp. infection and 122 of them died

(in-hospital mortality 15.1%). The crude incidence rate (Figure 2K) was highest in the west

(health region 5), followed by the east (health region 6). The crude incidence rate was lowest in

the central (health region 3 and 4) and upper north (health region 1). In the multivariable models,

health region was associated with the incidence of *Vibrio* spp. infection per 100,000 population

(Table S4). GPP, pig density and poultry density were not independently associated with the

incidence rate.

Among provinces where paired data were available, the yearly incidence rate of *Vibrio* spp.

infection in 2022 was lower than that between 2012-2015 by 25% (aIRR 0.75, 95%CI 0.66-0.85,

p<0.001).

Comparison with the national surveillance systems

In 2022, the total number of cases (4,407 vs. 3,573 cases) and deaths (1,219 vs. 157 deaths)

following *B. pseudomallei* infection diagnosed by culture was higher than those reported to the

national surveillance systems (Table 1). The total number of cases (867 vs. 383 cases) and deaths

(134 vs. 10 deaths) following *S. suis* infection diagnosed by culture was also higher. The total

number of deaths following fecal-oral transmitted NBDs diagnosed by culture (including 461 for

non-typhoidal salmonella, 122 for vibriosis, 4 for paratyphoid, 6 for typhoid and 4 for

shigellosis) were also higher than those reported to the national surveillance systems (0 deaths

for all relevant fecal-oral transmitted NBDs).

Discussion

Our findings provide evidence that the incidences of melioidosis and *S. suis* infection are

increasing and associated with a high number of deaths in Thailand in 2022. We also show that

fecal-oral transmitted NBDs including non-typhoidal salmonellosis, typhoid, shigellosis and

vibriosis are still present and associated with deaths, but their incidence rates are decreasing

compared to the data from 2012-2015. This study highlights the potential advantage of utilization

of routine microbiology and hospital admission data from hospitals. The local and timely data of

NBDs can supplement and monitor the performance of the national surveillance systems. The

accurate data can consequently identify diseases and areas with high burden, improve public

health interventions, and prioritize resource allocation.

The finding that more than 1,200 deaths following melioidosis in 2022 is alarming. This finding

is consistent with a previous modelling study predicting that the total number of deaths following

melioidosis could range from 1,259 to 6,678 in Thailand if all patients were tested with bacterial

culture and data were reported nationwide [28]. The increased incidence rate of melioidosis

could be associated with the increasing incidence of diabetes (the major risk factor of

melioidosis) and improvement of diagnostic stewardship (i.e. utilization of culture) and bacterial

identification in public hospitals in Thailand over time [16,29,30]. The association between

poultry density and melioidosis is unclear, and could be a spurious finding. Further studies and

actions to reduce the burden of melioidosis in Thailand are urgently needed [31].

Similarly, the increase in *S. suis* infection is alarming. This could be associated with an increase

in consumption of undercooked pork products [32-34] and an increase in infected meat in the

market [35]. The latter is a concern following the news of the large illegal pork imported to

Thailand since 2021 after the shortage of domestic pork due to the outbreak of African swine

fever in Thailand [36]. The DDC will utilize the data to additionally implement and enforce

behavioral interventions, education and food biosafety in the country [34].

The decrease of multiple fecal-oral transmitted diseases could be due to improvement in clean

water supply, sanitation and related health intervention programs over time [37,38]. The MoPH

and related stakeholders should maintain and strengthen the public health interventions to

decrease incidences of these infections further.

Our study and approach have several strengths. First, our study included most of the public

referral hospitals in the country. Second, we utilize microbiology laboratory data, which is highly

specific to the diagnosis of NBDs. Third, although our approach is semi-automatic, this approach

is easy to scale up in LMICs because the AMASS programme is open-access, highly-compatible,

and user-friendly without the need for data experts with adequate skills in statistical software

[17,19].

Our study and approach have several limitations. First, our approach included only inpatients in

the public referral hospitals. Therefore, our estimates did not include patients who did not require

hospitalization, and those who were hospitalized in private, military or university hospitals.

Nonetheless, majority of healthcare services in Thailand are in the public sector [39]. Second,

our approach is not applicable in settings where microbiology and hospital admission data are

not computerized. Third, our approach focused on bacterial culture results. Therefore, the

findings could be influenced by diagnostic stewardship and, capability and expertise of the

microbiology laboratories. Fourth, our approach utilizes summary data and could not evaluate

individual-level clinical data and microbiology laboratory data in details. Fifth, the in-hospital

mortality could be lower than the all-cause mortality because a preference to die at home is high

in some regions in Thailand [11].

In conclusion, the burden of melioidosis and *S. suis* infection are increasing in Thailand. Their

incidence rates are higher in some regions than in others. Specific public health interventions to

reduce the burden of melioidosis and *S. suis* infection are urgently required.

Acknowledgement

We gratefully acknowledge the laboratory team and IT team of all hospitals for their

participation and support.

Declaration of interest statement

The authors report there are no competing interests to declare.

Funding

This research was supported by the Wellcome Trust under Grant [number 224681/Z/21/Z]. For

the purpose of Open Access, the author has applied a CC BY public copyright licence to any

Author Accepted Manuscript version arising from this submission.

References

[1]   White AE, Tillman AR, Hedberg C, et al. Foodborne Illness Outbreaks Reported to
       National Surveillance, United States, 2009-2018. Emerg Infect Dis. 2022 Jun;28(6):1117-
       1127.

[2]   Nash K, Lai J, Sandhu K, et al. Impact of national COVID-19 restrictions on incidence of
       notifiable communicable diseases in England: an interrupted time series analysis. BMC
       Public Health. 2022 Dec 12;22(1):2318.

[3]   Wei F, Sheng W, Wu X, et al. Incidence of anogenital warts in Liuzhou, south China: a
       comparison of data from a prospective study and from the national surveillance system.
       Emerg Microbes Infect. 2017 Dec 20;6(12):e113.

[4]   Jayatilleke K. Challenges in Implementing Surveillance Tools of High-Income Countries
       (HICs) in Low Middle Income Countries (LMICs). Curr Treat Options Infect Dis.
       2020;12(3):191-201.

[5]   Vlieg WL, Fanoy EB, van Asten L, et al. Comparing national infectious disease
       surveillance systems: China and the Netherlands. BMC Public Health. 2017 May
       8;17(1):415.

[6]   Panackal AA, M'Ikanatha N M, Tsui FC, et al. Automatic electronic laboratory-based
       reporting of notifiable infectious diseases at a large health system. Emerg Infect Dis.
       2002 Jul;8(7):685-91.

[7]   Nguyen TQ, Thorpe L, Makki HA, et al. Benefits and barriers to electronic laboratory
       results reporting for notifiable diseases: the New York City Department of Health and
       Mental Hygiene experience. Am J Public Health. 2007 Apr;97 Suppl 1(Suppl 1):S142-5.

[8]   Sahal N, Reintjes R, Aro AR. Review article: communicable diseases surveillance

lessons learned from developed and developing countries: literature review. Scand J

Public Health. 2009 Mar;37(2):187-200.

[9]   Benson FG, Musekiwa A, Blumberg L, et al. Comparing laboratory surveillance with the

notifiable diseases surveillance system in South Africa. Int J Infect Dis. 2017 Jun;59:141-

147.

[10]   Chandrasekar K, Mahesan S, Bath PA. Notifiable disease surveillance in Sri Lanka and

the United Kingdom: a comparative study. Sri Lanka J Bio Med Inform. 2013;4(1):14-22.

[11]   Hantrakun V, Kongyu S, Klaytong P, et al. Clinical Epidemiology of 7126 Melioidosis

Patients in Thailand and the Implications for a National Notifiable Diseases Surveillance

System. Open Forum Infect Dis. 2019 Dec;6(12):ofz498.

[12]   Department of Disease Control, Ministry of Public Health, Thailand. Communicable

Disease Act B.E. 2558 (A.D. 2015) Available from:

https://ddc.moph.go.th/law_gcd_eng.php

[13]   Rattanaumpawan P, Wongkamhla T, Thamlikitkul V. Accuracy of ICD-10 Coding

System for Identifying Comorbidities and Infectious Conditions Using Data from a Thai

University Hospital Administrative Database. J Med Assoc Thai. 2016 Apr;99(4):368-73.

[14]   Sukanya C. Validity of Principal Diagnoses in Discharge Summaries and ICD-10 Coding

Assessments Based on National Health Data of Thailand. Healthc Inform Res. 2017

Oct;23(4):293-303.

[15]   Lim C, Hantrakun V, Klaytong P, et al. Frequency and mortality rate following

antimicrobial-resistant bloodstream infections in tertiary-care hospitals compared with

secondary-care hospitals. PLoS One. 2024;19(5):e0303132.

[16] Hinjoy S, Hantrakun V, Kongyu S, et al. Melioidosis in Thailand: Present and Future.

Trop Med Infect Dis. 2018;3(2):38.

[17] Lim C, Miliya T, Chansamouth V, et al. Automating the Generation of Antimicrobial

Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in

Seven Countries. J Med Internet Res. 2020 Oct 2;22(10):e19762.

[18] Lim C, Klaytong P, Hantrakun V, et al. Automating the Generation of Notifiable

Bacterial Disease Reports: Proof-of-Concept Study and Implementation in Six Hospitals

in Thailand. Am J Trop Med Hyg. 2024 Jul 3;111(1):151-155.

[19] Srisuphan V, Klaytong P, Rangsiwutisak C, et al. Local and timely antimicrobial

resistance data for local and national actions: the early implementation of an automated

tool for data analysis at local hospital level in Thailand. JAC Antimicrob Resist. 2023

Aug;5(4):dlad088.

[20] Tuamsuwan K, Chamawan P, Boonyarit P, et al. Frequency of antimicrobial-resistant

bloodstream infections in Thailand, 2022. medRxiv. 2024:2024.06.01.24308013.

[21] Jongudomsuk P, Srithamrongsawat S, Patcharanarumol W, et al. The Kingdom of

Thailand Health System Review 2015. Available from:

https://iris.who.int/bitstream/handle/10665/208216/9789290617136_eng.pdf

[22] Ministry of Public Health, Thailand. List of Healthcare Facilities under Health

Administration Division, Ministry of Public Health, Thailand 2023. 2023. Available

form: http://dmsic.moph.go.th/index/detail/9188

[23] Department of Medical Science, Ministry of Public Health, Thailand. Manual for

microbiology laboratories at regional and general hospitals. 2012. Available from:

http://narst.dmsc.moph.go.th/data/Idenbook.pdf

[24]   Austin PC, Stryhn H, Leckie G, et al. Measures of clustering and heterogeneity in

436   multilevel Poisson regression analyses of rates/count data. Stat Med. 2018 Feb

437   20;37(4):572-589.

438   [25]   National Statistical Office, Ministry of Digital Economy and Society, Thailand.

439   Statistical Yearbook Thailand 2023. 2023. Available form:

440   https://www.nso.go.th/public/e-book/Statistical-Yearbook/SYB-2023

441   [26]   Information and Communication Technology Center, Department of Livestock

442   Development, Ministry of Agriculture and Cooperatives, Thailand. Information of

443   animal-raising farmers at the provincial level, 2022. 2022. Available from:

444   https://ict.dld.go.th/webnew/index.php/th/service-ict/report/396-report-thailand-

445   livestock/reportservey2565/1711-province-2565

446   [27]   Department of Disease Control, Ministry of Public Health, Thailand. National Disease

447   Surveillance (Report 506). 2023. Available from: http://doe.moph.go.th/surdata/

448   [28]   Limmathurotsakul D, Golding N, Dance DA, et al. Predicted global distribution of

449   Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016 Jan 1;1(1).

450   [29]   Greer RC, Wangrangsimakul T, Amornchai P, et al. Misidentification of Burkholderia

451   pseudomallei as Acinetobacter species in northern Thailand. Trans R Soc Trop Med Hyg.

452   2019 Jan 1;113(1):48-51.

453   [30]   Mahikul W, White LJ, Poovorawan K, et al. Modelling population dynamics and

454   seasonal movement to assess and predict the burden of melioidosis. PLoS Negl Trop Dis.

455   2019 May;13(5):e0007380.

456   [31]   Department of Disease Control, Ministry of Public Health, Thailand. Guideline of

457   Melioidosis. 2021. Available from:

458   http://klb.ddc.moph.go.th/dataentry/handbook/form/129

459   [32]   Takamatsu D, Wongsawan K, Osaki M, et al. Streptococcus suis in humans, Thailand.

460   Emerg Infect Dis. 2008 Jan;14(1):181-3.

461   [33]   Takeuchi D, Kerdsin A, Akeda Y, et al. Impact of a Food Safety Campaign on

462   Streptococcus suis Infection in Humans in Thailand. Am J Trop Med Hyg. 2017

463   Jun;96(6):1370-1377.

464   [34]   Kerdsin A, Segura M, Fittipaldi N, et al. Sociocultural Factors Influencing Human

465   Streptococcus suis Disease in Southeast Asia. Foods. 2022 Apr 20;11(9).

466   [35]   Pappas G. Socio-economic, industrial and cultural parameters of pig-borne infections.

467   Clin Microbiol Infect. 2013 Jul;19(7):605-10.

468   [36]   Bangkok Post. Fighting pork smugglers. 2023. Available from:

469   https://www.bangkokpost.com/opinion/opinion/2667934/fighting-pork-smugglers

470   [37]   Boonsoong B, Sangpradub N, Barbour MT, et al. An implementation plan for using

471   biological indicators to improve assessment of water quality in Thailand. Environ Monit

472   Assess. 2010 Jun;165(1-4):205-15.

473   [38]   Techasaensiri C, Radhakrishnan A, Als D, et al. Typhoidal Salmonella Trends in

474   Thailand. Am J Trop Med Hyg. 2018 Sep;99(3_Suppl):64-71.

475   [39]   Sumriddetchkajorn K, Shimazaki K, Ono T, et al. Universal health coverage and primary

476   care, Thailand. Bull World Health Organ. 2019 Jun 1;97(6):415-422.

Figure legends

Figure 1. Health regions in Thailand

Footnote of figure 1. National Health Security Office (NHSO) Region 1 is in Chiang Mai, 2 in

Phitsanulok, 3 in Nakhonsawan, 4 in Saraburi, 5 in Ratchaburi, 6 in Rayong, 7 in Khon Kaen, 8

in Udon Thani, 9 in Nakonratchasima, 10 in Ubonratchathani, 11 in Suratthani, 12 in Songkhla

and 13 in Bangkok.

Figure 2. Incidence rate of cases with notifiable bacterial diseases diagnosed by culture per

100,000 population in 2022 in Thailand

Table 1. Total number of cases and deaths following selected notifiable bacterial diseases (NBDs) diagnosed by culture in 111 hospitals) compared with total number of cases and deaths with relevant notifiable diseases reported to the national surveillance systems (NSS) in Thailand in 2022.

Total number of cases *	This study	Relevant notifiable diseases in the NSS	NSS
Brucella spp. infection	11	Brucellosis	15
Burkholderia pseudomallei infection	4,407	Melioidosis	3,573
Corynebacterium diphtheriae infection	10	Diphtheria	0
Neisseria gonorrhoeae infection	25	Gonorrhea	6,915
Neisseria meningitidis infection	9	Meningococcal meningitis	19
Non-typhoidal *Salmonella* spp. and *Vibrio* spp. infection	4,501 and 809	Food poisoning and cholera	72,439 and 4
Salmonella enterica serovar Paratyphi infection	30	Paratyphoid	91
Salmonella enterica serovar Typhi infection	32	Typhoid	754
Shigella spp. infection	68	Bacillary dysentery	377
Streptococcus suis infection	867	*Streptococcus suis* infection	383
Total number of deaths			
Brucella spp. infection	1	Brucellosis	0
Burkholderia pseudomallei infection	1,219	Melioidosis	157
Corynebacterium diphtheriae infection	1	Diphtheria	0
Neisseria gonorrhoeae infection	0	Gonorrhea	0
Neisseria meningitidis infection	2	Meningococcal meningitis	3
Non-typhoidal *Salmonella* spp. and *Vibrio* spp. infection	461 and 122	Food poisoning and cholera	0 and 0
Salmonella enterica serovar Paratyphi infection	4	Paratyphoid	0
Salmonella enterica serovar Typhi infection	6	Typhoid	0
Shigella spp. infection	4	Bacillary dysentery	0
Streptococcus suis infection	134	*Streptococcus suis* infection	10

* Case was defined as an inpatient with a clinical specimen culture positive for a pathogen during the evaluation period, while the NSS included reports of suspected, probable and confirmed cases using a wide range of case definitions of each notifiable disease (Appendix B).

Health region
1
2
3
4
5
6
7
8
9
10
11
12
13

A

Incidence rate of patients with culture-confirmed *Brucella* spp. infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

B

Incidence rate of patients with culture-confirmed *Burkholderia pseudomallei* infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

C

Incidence rate of patients with culture-confirmed *Corynebacterium diphtheriae* infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

D

Incidence rate of patients with culture-confirmed *Neisseria gonorrheae* infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

E

Incidence rate of patients with culture-confirmed *Neisseria meningitidis* infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

F

Incidence rate of patients with culture-confirmed non-typhoidal *Salmonella* spp. infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

G

Incidence rate of patients with culture-confirmed *Salmonella enterica* serovar Paratyphi infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

H

Incidence rate of patients with culture-confirmed *Salmonella enterica* serovar Typhi infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

I

Incidence rate of patients with culture-confirmed *Shigella* spp. infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

J

Incidence rate of patients with culture-confirmed *Streptococcus suis* infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data

K

Incidence rate of patients with culture-confirmed *Vibrio* spp. infection per 100,000 population per year

>25.0
15.1–25.0
10.1–15.0
5.1–10.0
2.6–5.0
1.1–2.5
0.6–1.0
0.3–0.5
0.1–0.2
0
No data